Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

MRI in the diagnosis of fetal developmental brain abnormalities: the MERIDIAN diagnostic accuracy study.

Griffiths PD, Bradburn M, Campbell MJ, Cooper CL, Embleton N, Graham R, Hart AR, Jarvis D, Kilby MD, Lie M, Mason G, Mandefield L, Mooney C, Pennington R, Robson SC, Wailoo A.

Health Technol Assess. 2019 Sep;23(49):1-144. doi: 10.3310/hta23490.

2.

Identifying the Need for Good Practices in Health Technology Assessment: Summary of the ISPOR HTA Council Working Group Report on Good Practices in HTA.

Kristensen FB, Husereau D, Huić M, Drummond M, Berger ML, Bond K, Augustovski F, Booth A, Bridges JFP, Grimshaw J, IJzerman MJ, Jonsson E, Ollendorf DA, Rüther A, Siebert U, Sharma J, Wailoo A.

Value Health. 2019 Jan;22(1):13-20. doi: 10.1016/j.jval.2018.08.010. Epub 2018 Dec 13.

PMID:
30661627
3.

Mapping the FACT-B Instrument to EQ-5D-3L in Patients with Breast Cancer Using Adjusted Limited Dependent Variable Mixture Models versus Response Mapping.

Gray LA, Wailoo AJ, Hernandez Alava M.

Value Health. 2018 Dec;21(12):1399-1405. doi: 10.1016/j.jval.2018.06.006. Epub 2018 Aug 9.

4.

The Impact of Moving from EQ-5D-3L to -5L in NICE Technology Appraisals.

Pennington B, Hernandez-Alava M, Pudney S, Wailoo A.

Pharmacoeconomics. 2019 Jan;37(1):75-84. doi: 10.1007/s40273-018-0701-y.

5.

Development of Methods for the Mapping of Utilities Using Mixture Models: Mapping the AQLQ-S to the EQ-5D-5L and the HUI3 in Patients with Asthma.

Gray LA, Hernández Alava M, Wailoo AJ.

Value Health. 2018 Jun;21(6):748-757. doi: 10.1016/j.jval.2017.09.017. Epub 2017 Dec 14.

6.

What is the added value of ultrasound joint examination for monitoring synovitis in rheumatoid arthritis and can it be used to guide treatment decisions? A systematic review and cost-effectiveness analysis.

Simpson E, Hock E, Stevenson M, Wong R, Dracup N, Wailoo A, Conaghan P, Estrach C, Edwards C, Wakefield R.

Health Technol Assess. 2018 Apr;22(20):1-258. doi: 10.3310/hta22200. Review.

7.

Valuing health at the end of life: A review of stated preference studies in the social sciences literature.

Shah KK, Tsuchiya A, Wailoo AJ.

Soc Sci Med. 2018 May;204:39-50. doi: 10.1016/j.socscimed.2018.03.010. Epub 2018 Mar 7. Review.

PMID:
29558702
8.

The feasibility of early pulmonary rehabilitation and activity after COPD exacerbations: external pilot randomised controlled trial, qualitative case study and exploratory economic evaluation.

Cox M, O'Connor C, Biggs K, Hind D, Bortolami O, Franklin M, Collins B, Walters S, Wailoo A, Channell J, Albert P, Freeman U, Bourke S, Steiner M, Miles J, O'Brien T, McWilliams D, Schofield T, O'Reilly J, Hughes R.

Health Technol Assess. 2018 Mar;22(11):1-204. doi: 10.3310/hta22110.

9.

Cost-Effectiveness of Haemorrhoidal Artery Ligation versus Rubber Band Ligation for the Treatment of Grade II-III Haemorrhoids: Analysis Using Evidence from the HubBLe Trial.

Alshreef A, Wailoo AJ, Brown SR, Tiernan JP, Watson AJM, Biggs K, Bradburn M, Hind D.

Pharmacoecon Open. 2017 Sep;1(3):175-184. doi: 10.1007/s41669-017-0023-6.

10.

EQ-5D-5L versus EQ-5D-3L: The Impact on Cost Effectiveness in the United Kingdom.

Hernandez Alava M, Wailoo A, Grimm S, Pudney S, Gomes M, Sadique Z, Meads D, O'Dwyer J, Barton G, Irvine L.

Value Health. 2018 Jan;21(1):49-56. doi: 10.1016/j.jval.2017.09.004. Epub 2017 Oct 18.

11.

Does intensive management improve remission rates in patients with intermediate rheumatoid arthritis? (the TITRATE trial): study protocol for a randomised controlled trial.

Martin NH, Ibrahim F, Tom B, Galloway J, Wailoo A, Tosh J, Lempp H, Prothero L, Georgopoulou S, Sturt J, Scott DL; TITRATE Programme Investigators.

Trials. 2017 Dec 8;18(1):591. doi: 10.1186/s13063-017-2330-8.

12.

The clinical effectiveness and cost-effectiveness of treat-to-target strategies in rheumatoid arthritis: a systematic review and cost-effectiveness analysis.

Wailoo A, Hock ES, Stevenson M, Martyn-St James M, Rawdin A, Simpson E, Wong R, Dracup N, Scott DL, Young A.

Health Technol Assess. 2017 Nov;21(71):1-258. doi: 10.3310/hta21710. Review.

13.

UNITED KINGDOM CATHETER STUDY - PROTOCOL SYNOPSIS.

Briggs V, Solis-Trapala I, Wailoo A, McCullough K, Lambie M, Caskey FJ, Fotheringham J, Davies SJ, Wilkie M.

Perit Dial Int. 2017 Sep 28. pii: pdi.2017-00083. doi: 10.3747/pdi.2017-00083. [Epub ahead of print]

PMID:
28970368
14.

The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.

Grimm SE, Strong M, Brennan A, Wailoo AJ.

Pharmacoeconomics. 2017 Dec;35(12):1287-1296. doi: 10.1007/s40273-017-0562-9.

15.

How to design the cost-effectiveness appraisal process of new healthcare technologies to maximise population health: A conceptual framework.

Johannesen KM, Claxton K, Sculpher MJ, Wailoo AJ.

Health Econ. 2018 Feb;27(2):e41-e54. doi: 10.1002/hec.3561. Epub 2017 Aug 22.

16.

NICE DSU Technical Support Document 12: The Use of Health State Utility Values in Decision Models [Internet].

Ara R, Wailoo A.

London: National Institute for Health and Care Excellence (NICE); 2011 Jul.

17.

The Value of Innovation [Internet].

Claxton K, Longo R, Longworth L, McCabe C, Wailoo A.

London: National Institute for Health and Care Excellence (NICE); 2009 May 22.

18.

Review of Software for Decision Modelling [Internet].

Tosh J, Wailoo A.

London: National Institute for Health and Care Excellence (NICE); 2008 Jul 29.

19.

A Pilot Study of Value of Information Analysis to Support Research Recommendations for NICE [Internet].

Claxton K, Eggington S, Ginnelly L, Griffin S, McCabe C, Philips Z, Tappenden P, Wailoo A.

London: National Institute for Health and Care Excellence (NICE); 2005 Jun.

20.

Change in diagnostic confidence brought about by using in utero MRI for fetal structural brain pathology: analysis of the MERIDIAN cohort.

Griffiths PD, Bradburn M, Campbell MJ, Connolly DJA, Cooper CL, Jarvis D, Kilby MD, Mason G, Mooney C, Robson SC, Wailoo A; MERIDIAN Collaborative Group.

Clin Radiol. 2017 Jun;72(6):451-457. doi: 10.1016/j.crad.2017.01.009. Epub 2017 Feb 24.

21.

Mapping to Estimate Health-State Utility from Non-Preference-Based Outcome Measures: An ISPOR Good Practices for Outcomes Research Task Force Report.

Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, Botteman M, Busschbach J.

Value Health. 2017 Jan;20(1):18-27. doi: 10.1016/j.jval.2016.11.006. Erratum in: Value Health. 2017 Sep;20(8):1226.

22.

The Cost-effectiveness of Sequences of Biological Disease-modifying Antirheumatic Drug Treatment in England for Patients with Rheumatoid Arthritis Who Can Tolerate Methotrexate.

Stevenson MD, Wailoo AJ, Tosh JC, Hernandez-Alava M, Gibson LA, Stevens JW, Archer RJ, Simpson EL, Hock ES, Young A, Scott DL.

J Rheumatol. 2017 Jul;44(7):973-980. doi: 10.3899/jrheum.160941. Epub 2017 Feb 15. Review.

23.

Use of MRI in the diagnosis of fetal brain abnormalities in utero (MERIDIAN): a multicentre, prospective cohort study.

Griffiths PD, Bradburn M, Campbell MJ, Cooper CL, Graham R, Jarvis D, Kilby MD, Mason G, Mooney C, Robson SC, Wailoo A; MERIDIAN collaborative group.

Lancet. 2017 Feb 4;389(10068):538-546. doi: 10.1016/S0140-6736(16)31723-8. Epub 2016 Dec 15.

24.

The Role of Ultrasound Compared to Biopsy of Temporal Arteries in the Diagnosis and Treatment of Giant Cell Arteritis (TABUL): a diagnostic accuracy and cost-effectiveness study.

Luqmani R, Lee E, Singh S, Gillett M, Schmidt WA, Bradburn M, Dasgupta B, Diamantopoulos AP, Forrester-Barker W, Hamilton W, Masters S, McDonald B, McNally E, Pease C, Piper J, Salmon J, Wailoo A, Wolfe K, Hutchings A.

Health Technol Assess. 2016 Nov;20(90):1-238.

25.

The HubBLe Trial: haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for symptomatic second- and third-degree haemorrhoids: a multicentre randomised controlled trial and health-economic evaluation.

Brown S, Tiernan J, Biggs K, Hind D, Shephard N, Bradburn M, Wailoo A, Alshreef A, Swaby L, Watson A, Radley S, Jones O, Skaife P, Agarwal A, Giordano P, Lamah M, Cartmell M, Davies J, Faiz O, Nugent K, Clarke A, MacDonald A, Conaghan P, Ziprin P, Makhija R.

Health Technol Assess. 2016 Nov;20(88):1-150.

26.
27.

The Cost-Effectiveness of Antibiotic Prophylaxis for Patients at Risk of Infective Endocarditis.

Franklin M, Wailoo A, Dayer MJ, Jones S, Prendergast B, Baddour LM, Lockhart PB, Thornhill MH.

Circulation. 2016 Nov 15;134(20):1568-1578.

28.

Consensus Decision Models for Biologics in Rheumatoid and Psoriatic Arthritis: Recommendations of a Multidisciplinary Working Party.

Madan J, Ades T, Barton P, Bojke L, Choy E, Helliwell P, Jobanputra P, Stein K, Stevens A, Tosh J, Verstappen S, Wailoo A.

Rheumatol Ther. 2015 Dec;2(2):113-125. Epub 2015 Nov 25.

29.

NICE DSU Technical Support Document 15: Cost-Effectiveness Modelling Using Patient-Level Simulation [Internet].

Davis S, Stevenson M, Tappenden P, Wailoo A.

London: National Institute for Health and Care Excellence (NICE); 2014 Apr.

30.

Haemorrhoidal artery ligation versus rubber band ligation for the management of symptomatic second-degree and third-degree haemorrhoids (HubBLe): a multicentre, open-label, randomised controlled trial.

Brown SR, Tiernan JP, Watson AJM, Biggs K, Shephard N, Wailoo AJ, Bradburn M, Alshreef A, Hind D; HubBLe Study team.

Lancet. 2016 Jul 23;388(10042):356-364. doi: 10.1016/S0140-6736(16)30584-0. Epub 2016 May 25. Erratum in: Lancet. 2016 Jul 23;388(10042):342.

31.
32.

Modeling Health State Utility Values in Ankylosing Spondylitis: Comparisons of Direct and Indirect Methods.

Wailoo A, Hernández M, Philips C, Brophy S, Siebert S.

Value Health. 2015 Jun;18(4):425-31. doi: 10.1016/j.jval.2015.02.016. Epub 2015 May 16.

33.

Valuing health at the end of life: a stated preference discrete choice experiment.

Shah KK, Tsuchiya A, Wailoo AJ.

Soc Sci Med. 2015 Jan;124:48-56. doi: 10.1016/j.socscimed.2014.11.022. Epub 2014 Nov 13.

34.

Adjusting for treatment switching in randomised controlled trials - A simulation study and a simplified two-stage method.

Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL, Campbell MJ.

Stat Methods Med Res. 2017 Apr;26(2):724-751. doi: 10.1177/0962280214557578. Epub 2014 Nov 21.

PMID:
25416688
35.

The Cost-Effectiveness of Biologic Dmards in Patients With Severe or Mild-To-Severe Rheumatoid Arthritis After Conventional Dmards.

Wailoo AJ, Stevenson M, Tosh J, Hernández M, Stevens JW, Archer R, Simpson E, Everson HE, Scott D, Young A, Paisley S, Williams K.

Value Health. 2014 Nov;17(7):A380. doi: 10.1016/j.jval.2014.08.2611. Epub 2014 Oct 26. No abstract available.

36.

Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experiment.

Skedgel C, Wailoo A, Akehurst R.

Med Decis Making. 2015 Jan;35(1):94-105. doi: 10.1177/0272989X14547915. Epub 2014 Aug 21.

PMID:
25145575
37.

The safety of intravitreal bevacizumab monotherapy in adult ophthalmic conditions: systematic review.

Poku E, Rathbone J, Wong R, Everson-Hock E, Essat M, Pandor A, Wailoo A.

BMJ Open. 2014 Jul 17;4(7):e005244. doi: 10.1136/bmjopen-2014-005244. Review.

38.

Health Assessment Questionnaire disability progression in early rheumatoid arthritis: systematic review and analysis of two inception cohorts.

Norton S, Fu B, Scott DL, Deighton C, Symmons DP, Wailoo AJ, Tosh J, Lunt M, Davies R, Young A, Verstappen SM.

Semin Arthritis Rheum. 2014 Oct;44(2):131-44. doi: 10.1016/j.semarthrit.2014.05.003. Epub 2014 May 9. Review.

39.

Cost-effectiveness of treatment strategies using combination disease-modifying anti-rheumatic drugs and glucocorticoids in early rheumatoid arthritis.

Wailoo A, Hernández Alava M, Scott IC, Ibrahim F, Scott DL.

Rheumatology (Oxford). 2014 Oct;53(10):1773-7. doi: 10.1093/rheumatology/keu039. Epub 2014 Apr 25.

PMID:
24771112
40.

Modelling the relationship between the WOMAC Osteoarthritis Index and EQ-5D.

Wailoo A, Hernandez Alava M, Escobar Martinez A.

Health Qual Life Outcomes. 2014 Mar 12;12:37. doi: 10.1186/1477-7525-12-37.

41.

Adjusting survival time estimates to account for treatment switching in randomized controlled trials--an economic evaluation context: methods, limitations, and recommendations.

Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, Akehurst RL, Campbell MJ.

Med Decis Making. 2014 Apr;34(3):387-402. doi: 10.1177/0272989X13520192. Epub 2014 Jan 21.

PMID:
24449433
42.

A comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes.

Hernández Alava M, Wailoo A, Wolfe F, Michaud K.

Med Decis Making. 2014 Oct;34(7):919-30. doi: 10.1177/0272989X13500720. Epub 2013 Sep 11.

PMID:
24025662
43.

Good practice guidelines for the use of statistical regression models in economic evaluations.

Kearns B, Ara R, Wailoo A, Manca A, Alava MH, Abrams K, Campbell M.

Pharmacoeconomics. 2013 Aug;31(8):643-52. doi: 10.1007/s40273-013-0069-y. Review.

PMID:
23807751
44.

Choosing vs. allocating: discrete choice experiments and constant-sum paired comparisons for the elicitation of societal preferences.

Skedgel CD, Wailoo AJ, Akehurst RL.

Health Expect. 2015 Oct;18(5):1227-40. doi: 10.1111/hex.12098. Epub 2013 Jun 12.

45.

Variations in primary care prescribing: lessons to be learnt for GP commissioners.

Houten R, Wailoo A, Jonsson P, McLeod C.

Prim Health Care Res Dev. 2014 Jan;15(1):111-6. doi: 10.1017/S1463423613000261. Epub 2013 May 29.

PMID:
23714273
46.

Valuing health at the end of life: an empirical study of public preferences.

Shah KK, Tsuchiya A, Wailoo AJ.

Eur J Health Econ. 2014 May;15(4):389-99. doi: 10.1007/s10198-013-0482-3. Epub 2013 May 9.

PMID:
23657476
47.

A review of the psychometric performance of the EQ-5D in people with urinary incontinence.

Davis S, Wailoo A.

Health Qual Life Outcomes. 2013 Feb 18;11:20. doi: 10.1186/1477-7525-11-20. Review.

48.

The relationship between EQ-5D, HAQ and pain in patients with rheumatoid arthritis.

Hernández Alava M, Wailoo A, Wolfe F, Michaud K.

Rheumatology (Oxford). 2013 May;52(5):944-50. doi: 10.1093/rheumatology/kes400. Epub 2013 Jan 21.

49.

The HubBLe trial: haemorrhoidal artery ligation (HAL) versus rubber band ligation (RBL) for haemorrhoids.

Tiernan J, Hind D, Watson A, Wailoo AJ, Bradburn M, Shephard N, Biggs K, Brown S.

BMC Gastroenterol. 2012 Oct 25;12:153. doi: 10.1186/1471-230X-12-153.

50.

Payers' views on treating-to-target in rheumatoid arthritis: an English perspective.

Scott IC, Wailoo A, Scott DL.

Clin Exp Rheumatol. 2012 Jul-Aug;30(4 Suppl 73):S85-90. Epub 2012 Oct 16.

PMID:
23078814

Supplemental Content

Loading ...
Support Center